Court of Appeals for the Federal Circuit affirms Delaware District Court’s decision



Téléchargez gratuitement le guide
Dopez vos plus-values
Brussels (Belgium), May 23rd, 2018 – 18.00 CEST – UCB announces that in a decision released today, the Court of Appeals for the Federal Circuit (CAFC) has affirmed the Delaware District Court and confirmed the validity of U.S. patent RE38,551 related to Vimpat® (lacosamide), UCB’s anti-epileptic drug.

"We are pleased with the CAFC decision," said Anna Richo UCB’s Executive Vice President and General Counsel. "This confirms the strength of our intellectual property for Vimpat® and maintains UCB’s exclusivity position until March 2022.” This decision supports UCB’s commitment to epilepsy patients and UCB's ability to deliver Vimpat® to patients.

Téléchargez gratuitement le guide
Dopez vos plus-values

Recommander à vos amis
  • gplus
  • pinterest